Abbott Laboratories (ABT)

45.68
NYSE : Health Care
Prev Close 45.40
Day Low/High 45.23 / 45.68
52 Wk Low/High 36.76 / 45.79
Avg Volume 9.25M
Exchange NYSE
Shares Outstanding 1.73B
Market Cap 78.45B
EPS 0.90
P/E Ratio 63.94
Div & Yield 1.06 (2.30%)

Latest News

High-Powered Insiders Are Buying These 5 Stocks; Should You?

High-Powered Insiders Are Buying These 5 Stocks; Should You?

Insiders at these companies -- including Tailored Brands and Qualcomm -- have been scooping up shares of their own stock lately.

These Are the 5 Perfect Dividend Stocks for Today's Market

These Are the 5 Perfect Dividend Stocks for Today's Market

Abbott Labs is one of four names to own.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

These stocks are indicating a change in direction.

U.S. FDA Grants Abbott The First Commercial Authorization For A Molecular Test To Detect Zika Virus Using Whole Blood

U.S. FDA Grants Abbott The First Commercial Authorization For A Molecular Test To Detect Zika Virus Using Whole Blood

FDA EXPANDS EMERGENCY USE AUTHORIZATION FOR ABBOTT REALTIME ZIKA MOLECULAR TEST BEYOND PREVIOUS AUTHORIZATION TO IDENTIFY ZIKA USING SERUM, PLASMA AND URINE ONLY

Abbott Announces U.S. Approval For Its Assurity MRI™ Pacemaker, The World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker

Abbott Announces U.S. Approval For Its Assurity MRI™ Pacemaker, The World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker

FDA APPROVAL BROADENS PATIENT ACCESS TO THE COMPANY'S MRI-READY PACEMAKER, WHICH OFFERS OUTSTANDING LONGEVITY AND IMPROVES PHYSICIAN MONITORING

How Trump's Targeting of High-Tech Immigrant Workers Stands to Damage the U.S. Economy

How Trump's Targeting of High-Tech Immigrant Workers Stands to Damage the U.S. Economy

The president appears to be readying yet another executive order, to prevent skilled immigrants from working at U.S. companies or starting businesses here, but more H-1B visas may be needed.

A Play on Intel's Breakdown

A Play on Intel's Breakdown

With trend favoring the bears, I'm favoring a bearish call spread.

Drugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees

Drugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees

Here are the winning banks.

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs' shares fell nearly 1% in premarket trading after the company reported mixed earnings results.

Market Recon: The President's Actions Renew Belief in the Agenda

Market Recon: The President's Actions Renew Belief in the Agenda

Remember the old saying "the business of America, is business"? This is what we were all taught on the way up.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

New Study Demonstrates Spinal Cord Stimulation Can Reduce Or Stabilize Opioid Use Among Chronic Pain Patients

New Study Demonstrates Spinal Cord Stimulation Can Reduce Or Stabilize Opioid Use Among Chronic Pain Patients

ONE YEAR AFTER IMPLANT, 93 PERCENT OF PATIENTS WHO CONTINUED SCS THERAPY HAD LOWER AVERAGE DAILY MORPHINE-EQUIVALENT DOSES THAN PATIENTS WHO HAD THEIR SCS SYSTEM REMOVED

Abbott Announces European Launch Of The Proclaim™ DRG Neurostimulation System For The Management Of Chronic Neuropathic Pain

Abbott Announces European Launch Of The Proclaim™ DRG Neurostimulation System For The Management Of Chronic Neuropathic Pain

SYSTEM COMBINES SUPERIOR PAIN RELIEF WITH AN INTUITIVE APPLE™ TECHNOLOGY PROGRAMMING PLATFORM

New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success Over Traditional Spinal Cord Stimulation

New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success Over Traditional Spinal Cord Stimulation

ACCURATE STUDY CONFIRMS DRG STIMULATION PROVIDES SUPERIOR, TARGETED AND CONSISTENT PAIN RELIEF FOR PATIENTS WITH COMPLEX REGIONAL PAIN SYNDROME

Abbott Announces U.S. Launch And First Commercial Use Of The New EnSite™ Precision Cardiac Mapping System

Abbott Announces U.S. Launch And First Commercial Use Of The New EnSite™ Precision Cardiac Mapping System

ENHANCED SYSTEM ALLOWS BETTER THREE-DIMENSIONAL IMAGES OF ARRHYTHMIAS IN THE HEART

Abbott Announces CE Mark For Its

Abbott Announces CE Mark For Its "Alinity S" Blood And Plasma Screening System

INNOVATIVE SOLUTION DESIGNED FOR BLOOD AND PLASMA SCREENING MAINTAINS HIGHEST LEVELS OF ACCURACY WHILE SUBSTANTIALLY INCREASING PRODUCTIVITY

Abbott Announces CE Mark For Its Alinity Ci-series Diagnostic Systems

Abbott Announces CE Mark For Its Alinity Ci-series Diagnostic Systems

NEXT GENERATION OF HARMONIZED SYSTEMS, COMBINED WITH RECENTLY LAUNCHED ALINIQ PROFESSIONAL SERVICES, PROVIDE A UNIQUE SOLUTION TO HELP LABS AND HOSPITAL SYSTEMS ACHIEVE MEASURABLY BETTER HEALTHCARE PERFORMANCE

What Exactly Are Investors Missing Out On?

Statistically, Friday's rally was not the best one.

Check These Dividend Dates

Must-own dates for some notable names.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Husband of Top Trump Adviser Conway Said to Be a Finalist for U.S. Solicitor General

Husband of Top Trump Adviser Conway Said to Be a Finalist for U.S. Solicitor General

The lawyer is the husband of Trump adviser Kellyanne Conway and works in corporate litigation.

Abbott Labs: Diagnosing Growth in 2017

Abbott Labs: Diagnosing Growth in 2017

ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?

Don't Be So Quick to Be Bullish

The ETF put/call ratio chart indicates some limited upside.

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

The S&P 500 may be ending 2016 with double-digit gains, but almost a third of the index's individual stocks are actually down this year. Here's how to avoid the laggards.

Abbott Acquisition Of St. Jude Medical Set To Close On January 4, 2017

Abbott Acquisition Of St. Jude Medical Set To Close On January 4, 2017

- CREATES A PREMIER MEDICAL DEVICE BUSINESS WITH LEADING POSITIONS IN CARDIOVASCULAR AND NEUROMODULATION MARKETS